• Morgan Stanley advises investors to hold Bristol-Myers Squibb (NYSE: BMY) despite its "Underweight" rating, citing the company's focused execution and innovative medicines.
• Bristol-Myers Squibb's growth portfolio increased by 15% year-over-year in the fourth quarter of 2025, nearly offsetting a $4 billion revenue decline from its legacy portfolio.
• The company's total revenue remained stable at approximately $12.5 billion in the fourth quarter, with a stock price increase of 3.44%.

On February 6, 2026, Morgan Stanley maintained its "Underweight" rating for Bristol-Myers Squibb (NYSE: BMY), advising investors to hold the stock. At the time, BMY was priced at around $61.46. Bristol-Myers Squibb is a global biopharmaceutical company known for its innovative medicines. It competes with other pharmaceutical giants like Pfizer and Merck.

Bristol-Myers Squibb's strategy of "focused execution" in 2025 has set a positive tone for 2026. The company has emphasized the importance of its newer brands and late-stage pipeline catalysts. Despite challenges from loss-of-exclusivity (LOE) headwinds, the company plans to counterbalance these with strict cost management.

In the fourth quarter of 2025, Bristol-Myers Squibb reported a strong performance. The growth portfolio increased by 15% year-over-year in the quarter and 17% for the entire year. This growth nearly offset a $4 billion revenue decline from the legacy portfolio, as highlighted by CEO Chris Boerner.

CFO David Elkins noted that the fourth-quarter total revenue remained stable at approximately $12.5 billion. The stock price for BMY is currently $61.57, reflecting a 3.44% increase. The stock has fluctuated between $59.77 and $61.86 today, with a market capitalization of about $125.34 billion.

BMY's stock has seen a 52-week high of $63.33 and a low of $42.52. The trading volume stands at 5.4 million shares. Despite the "Underweight" rating, the company's strategic focus and financial performance suggest potential for future growth.